Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluation of [123I] AV151 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease (AD) in Comparison to Healthy Subjects
Authors not listed
Institute for Neurodegenerative Disorders · 2007
Abstract
Purpose:
The main objectives of this proposal are as follows:
To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
To perform blood metabolite characterization of 123-I AV151 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of 123-I AV151 as a single photon computed tomography (SPECT) brain imaging agent
Evaluate the test/retest reproducibility of 123-I AV151 and SPECT in AD subjects and healthy controls
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2007). Evaluation of [123I] AV151 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease (AD) in Comparison to Healthy Subjects. <em>Institute for Neurodegenerative Disorders</em>. https://clinicaltrials.gov/study/NCT00605046
Vancouver
Anonymous. Evaluation of [123I] AV151 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease (AD) in Comparison to Healthy Subjects. Institute for Neurodegenerative Disorders. 2007.
BibTeX
@misc{anon2007Evalua,
title = {Evaluation of [123I] AV151 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease (AD) in Comparison to Healthy Subjects},
author = {Anonymous},
journal = {Institute for Neurodegenerative Disorders},
year = {2007},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Institute for Neurodegenerative Disorders 2007
Open access · US-GOV
Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Invicro 2018
Open access · US-GOV
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).
Cureus 2025
Open access · CC-BY
Analytical Review on Normal Brain Aging, Alzheimer’s Disease, and Stage 4S Neuroblastoma: Novel Insights Into Neuroprotection, Neurodegeneration, and Spontaneous Regression
Massachusetts General Hospital 2022
Open access · US-GOV
Assess the Brain Levels of Fibrin in Alzheimer's Disease and Its Related Dementias Subjects Using 64Cu-FBP8 PET
Molecular Neurobiology 2025
Open access · CC-BY
Senolytics as Modulators of Critical Signaling Pathways: a Promising Strategy to Combat Brain Aging and Neurodegenerative Disorders
Circulation 2016
Open access · OA